Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of… Jun 27, 2022
Cybin Deal Signals That Psychedelic ‘Majors’ Are Eyeing Complimentary Assets From Cash-Starved Peers Jun 7, 2022
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program Jun 3, 2022
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major… May 31, 2022
